Skip to content

Fighting to Preserve the Benefits of the 340B Program

  • About Us
  • Contact Us
Top Bar Menu
Facebook page opens in new windowTwitter page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News

FTC Logo

RWC-340B Submits Comments to Federal Trade Commission

Drug Pricing, RegulationsBy Amber TynanApril 22, 2022

As you may know, the Federal Trade Commission recently requested public comments on the impacts of Pharmacy Benefit Managers’ practices, affecting drug affordability and access.   Today, RWC-340B submitted detailed…

Gilead

RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.

Congress, Drug Pricing, HHS, HRSA, Regulations, RWC-340BBy Amber TynanApril 15, 2022

A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on.   On…

Johnson Johnson Logo

Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies

Congress, Drug Pricing, News, RWC-340BBy Amber TynanMarch 23, 2022

By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…

RWC 340B Logo hi res 002

RWC-340B Responds to Gilead’s Conditions on 340B Contract Pharmacy

Drug Pricing, RWC-340BBy Amber TynanMarch 17, 2022

As reported today in the 340B Report, Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy (for subscribers only), and RWC-340B President Shannon Stephenson is quoted throughout (excerpt below). Ryan White…

Gilead

Gilead to Restrict Access to 340B Prices at Contract Pharmacies for Branded Hep-C Drugs; AbbVie Adds Imbruvica to Restrictive Contract Pharmacy Policy

Drug Pricing, RWC-340BBy Amber TynanMarch 17, 2022

By letter dated March 15, 2022, Gilead announced that, effective May 2, 2022, it will implement a new “Contract Pharmacy Integrity Initiative” under which it will no longer honor  contract…

Gilead

RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies

Drug Pricing, News, RWC-340BBy Amber TynanMarch 17, 2022

Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…

Spanberger

Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes

Drug Pricing, HHS, NewsBy Amber TynanJanuary 26, 2022

In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…

thought catalog kkysaOcVE94 unsplash

BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs

Drug Pricing, NewsBy Andrea JeriaJanuary 20, 2022

By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…

eye g4f3076735 1920

Second Sight Updates 340B ESP Terms of Use

Drug Pricing, NewsBy Andrea JeriaJanuary 6, 2022

In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform.  There…

volodymyr hryshchenko m1Hq4ibP9rc unsplash

New AbbVie and Lilly Contract Pharmacy Policies

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaJanuary 6, 2022

AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…

→12345…
678910111213
14→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset